A therapeutics delivery system, and methods of making and using same, are disclosed for environments that rapidly clear any injected therapeutics, such as a patient's eye. The therapeutics delivery system releases the drug in a therapeutically effective concentration for a desired duration of time with a predefined drug kinetics. In one embodiment, the embodiments of the present disclosure release a therapeutically effective concentration for a longer time period than other delivery systems, for instance from a day to a week. Certain embodiments comprise a therapeutics dispensing device comprising a biodissolvable hydrogel matrix for long term drug release that allows the device to be placed directly at the injured site, e.g., onto the surface at or near the injury, and retained there rather than through injection, whether locally or systematically.

The present invention provides a method for stabilizing a fractured bone. The method includes positioning an elongate rod in the medullary canal of the fractured bone and forming a passageway through the cortex of the bone. The passageway extends from the exterior surface of the bone to the medullary canal of the bone. The method also includes creating a bonding region on the elongate rod. The bonding region is generally aligned with the passageway of the cortex. Furthermore, the method includes positioning a fastener in the passageway of the cortex and on the bonding region of the elongate rod and thermally bonding the fastener to the bonding region of the elongate rod while the fastener is positioned in the passageway of the cortex.

A therapeutics delivery system, and methods of making and using same, are disclosed for environments that rapidly clear any injected therapeutics, such as a patient's eye. The therapeutics delivery system releases the drug in a therapeutically effective concentration for a desired duration of time with a predefined drug kinetics. In one embodiment, the embodiments of the present disclosure release a therapeutically effective concentration for a longer time period than other delivery systems, for instance from a day to a week. Certain embodiments comprise a therapeutics dispensing device comprising a biodissolvable hydrogel matrix for long term drug release that allows the device to be placed directly at the injured site, e.g., onto the surface at or near the injury, and retained there rather than through injection, whether locally or systematically.

A valved conduit including a bioprosthetic valve, such as a heart valve, and a tubular conduit sealed with a bioresorbable material. The bioprosthetic heart valve includes prosthetic tissue that has been treated such that the tissue may be stored dry for extended periods without degradation of functionality of the valve. The bioprosthetic heart valve may have separate bovine pericardial leaflets or a whole porcine valve. The sealed conduit includes a tubular matrix impregnated with a bioresorbable medium such as gelatin or collagen. The valved conduit is stored dry in packaging in which a desiccant pouch is supplied having a capacity for absorbing moisture within the packaging limited to avoid drying the bioprosthetic tissue out beyond a point where its ability to function in the bioprosthetic heart valve is compromised. The heart valve may be sewn within the sealed conduit or coupled thereto with a snap-fit connection.

Tissue engineered constructs and methods for fabricating the disclosed constructs are provided. Some of the disclosed tissue engineered constructs are designed to fill a void in the body due to surgical resection, for example from mastectomy or lumpectomy, wounds and the like. Some disclosed constructs comprise one or more projections designed to mimic the appearance of a structural feature when implanted into a host.

A valved conduit including a bioprosthetic valve, such as a heart valve, and a tubular conduit sealed with a bioresorbable material. The bioprosthetic heart valve includes prosthetic tissue that has been treated such that the tissue may be stored dry for extended periods without degradation of functionality of the valve. The bioprosthetic heart valve may have separate bovine pericardial leaflets or a whole porcine valve. The sealed conduit includes a tubular matrix impregnated with a bioresorbable medium such as gelatin or collagen. The valved conduit is stored dry in packaging in which a desiccant pouch is supplied having a capacity for absorbing moisture within the packaging limited to avoid drying the bioprosthetic tissue out beyond a point where its ability to function in the bioprosthetic heart valve is compromised. The heart valve may be sewn within the sealed conduit or coupled thereto with a snap-fit connection.

A knee arthroplasty system may have a femoral joint prosthesis with a femoral bone engagement surface with an anterior portion, a posterior portion, and a distal portion that connects the anterior portion to the posterior portion. A first femoral anchoring member may protrude from the distal portion, and may be connected to the anterior portion with a primary femoral web. A tibial resection guide may have a base member and a guide member with a slot that guides a cutting blade to resect the tibial plateau. The guide member may slide along an arcuate path relative to the base member.

A knee arthroplasty system may have a femoral joint prosthesis with a femoral bone engagement surface with an anterior portion, a posterior portion, and a distal portion that connects the anterior portion to the posterior portion. A first femoral anchoring member may protrude from the distal portion, and may be connected to the anterior portion with a primary femoral web. A tibial resection guide may have a base member and a guide member with a slot that guides a cutting blade to resect the tibial plateau. The guide member may slide along an arcuate path relative to the base member.

A prosthesis may have an articulating component formed via casting and a 3D printed bone anchoring component with a joint-facing side and a bone-facing side. The bone-facing side may have a bone engagement surface with a porous structure with pores selected to facilitate in-growth of the bone into the pores. The bone facing side may further have a surface layer of Titanium Dioxide nanotubes. The joint-facing side may be secured to the articulating component by melting Titanium nanoparticles at a temperature below the melting temperatures of the major constituents of the articulating component and/or the bone anchoring component, such as Cobalt, Chromium, and/or Titanium, so as to avoid significantly modifying the crystalline structures of the articulating component and/or the bone anchoring component. The melting temperature of the Titanium nanoparticles may be about 500 C.

This invention is directed to an assembled implant comprising two or more portions of bone that are held together in appropriate juxtaposition with one or more biocompatible pins to form a graft unit. Preferably, the pins are cortical bone pins. Typically, the cortical pins are press-fitted into appropriately sized holes in the bone portions to achieve an interference fit. The bone portions are allograft or xenograft.